retatrutide

triple-agonist · glp-1 / gip / glucagon

Lilly's investigational triple-agonist activating glp-1, gip and glucagon receptors in a single 39-residue scaffold. The current centerpiece of metabolic research.

vial size

for laboratory use only — not for human consumption. ships from tallinn within 24 h, EU delivery in 48 h.

research monograph

what the literature shows.

A condensed monograph drawn from preclinical and clinical literature. Cited mechanisms, specifications and the research case for retatrutide.

01 · mechanism of action

Retatrutide (LY3437943) is an experimental triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors — a previously unique combination in peptide research. In preclinical animal studies on obese mice and rats, retatrutide led to body-weight reductions of 20–30 % within 12 weeks, significantly stronger than semaglutide comparison groups. The combination of GLP-1 and glucagon agonism increased energy expenditure through thermogenic activation in brown adipose tissue. In Phase 1 and Phase 2 human studies (2022–2023) subjects showed weight reductions of up to 24 % of baseline over 48 weeks. Additional animal data show improvements in insulin sensitivity, reduction of hepatic fat (NASH models), and cardioprotective effects through improved lipid profiles.

02 · product specifications

Available in 10 mg and 20 mg lyophilized vials at ≥ 99.4 % purity (HPLC-tested). Suitable for advanced in-vitro studies on receptor pharmacology and metabolic signal transduction. Reconstitute in bacteriostatic water or 0.9 % NaCl. Long-term storage at −20 °C, protected from light.

03 · research advantages

Retatrutide represents the next generation of metabolic research molecules. As the only available triple agonist, it enables simultaneous investigation of three metabolic receptor pathways in one experiment. The Phase 2 clinical data underline its extraordinary relevance to obesity and metabolic research.

datasheet

full specification.

Identity, mass, purity reference and storage profile for the current lot of retatrutide. For laboratory use only.

catalog no.: PH-1014-R
cas: 2381089-83-2
molecular weight: 4731.42 g/mol
purity (hplc): ≥ 99.4 % (hplc)
endotoxin: < 0.5 eu/mg (lal)
sequence: 39-residue analogue (lilly LY3437943)
residues: 39 aa
appearance: white lyophilized powder
reconstitution: bacteriostatic water · 0.9 % nacl
stability (reconstituted): 28 d at 2–8 °c
shelf life (lyophilized): 24 m at −20 °c
storage: −20 °c, protect from light
current lot: rta-260411
current exp.: 11 / 2027
lead time: ships in 24 h

same series · metabolic

from the same bench.

full catalog

back to catalog